Gerresheimer's Institutional Bet: A Wager on Rock Bottom

Amid a 70% stock plunge and accounting scandal, Gerresheimer faces covenant defaults, asset sales, and legal probes while some institutions accumulate shares.

While Gerresheimer AG's financial reporting remains frozen and its stock price decimated, a notable shift is occurring in its shareholder registry. Despite a 70% plunge over the past twelve months, institutional investors like the CastleKnight Master Fund and Deka Investment have recently disclosed new stakes. This accumulation suggests some major players view the extensive bad news—from an SDAX delisting to a full-blown accounting scandal—as already reflected in a share price now hovering around €17.22.

The core of the crisis remains a severe breach of accounting rules. An independent law firm confirmed systematic violations involving "bill-and-hold" agreements, where revenue was recognized before goods were shipped, contravening IFRS standards. These erroneous bookings for 2024 amount to €35 million in sales and require a €24 million correction to adjusted EBITDA. The fallout has ensnared auditor KPMG, which issued an unqualified audit opinion for the flawed 2024 accounts. Germany's audit oversight body, APAS, has now opened a professional misconduct investigation against the firm.

This accounting chaos has triggered a chain reaction with severe operational consequences. The failure to publish audited financial statements for the fiscal year ending November 2024 has put Gerresheimer in technical default on its loan covenants. Management is currently locked in negotiations to secure extensions and prevent lenders from calling in credit lines. With no certified numbers available, the company's entire reporting calendar has stalled. The first-quarter update originally slated for April 16 is postponed, as is the Annual General Meeting scheduled for June 3, with no new dates set.

To shore up liquidity, Gerresheimer has initiated a sale process for its US primary packaging unit, Centor, which is carried on the books at €292 million. Morgan Stanley is advising on the divestment. Concurrently, the group plans non-cash impairment charges totaling between €220 million and €240 million, largely tied to technology projects at subsidiary Sensile Medical AG and assets linked to the planned closure of its Chicago Heights plant by the end of 2026.

Legal pressures are mounting alongside the financial ones. The German shareholder association DSW is commissioning an expert report to assess potential damage claims against former CEO Dietmar Siemssen, former CFO Bernd Metzner, and the supervisory board's audit committee. Meanwhile, Grant Thornton is conducting a parallel review of the company's books for both 2024 and 2025, alongside an ongoing investigation by German financial regulator BaFin.

All critical paths now converge on June 2026. By then, Gerresheimer must finally deliver its audited financial statements for 2025 and demonstrate it has secured its banking relationships. Only with these foundations in place can the company's conditional revenue guidance of €2.3 billion to €2.4 billion for 2026 gain any credibility. The half-year report, tentatively penciled in for July 14, 2026, remains entirely dependent on this outcome. For the institutional buyers betting now, June represents the moment of truth that will determine whether their gamble on a battered stock was prescient or perilous.